EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Wogonin Reverses Cisplatin Resistance of Non‐Small Cell Lung Cancer by Inducing Ferroptosis and Disrupting Mitochondrial Quality Control: A Potential Role of the HO ‐1/ PPARγ / PGC ‐1α Axis

Zicheng Liang, Xiayi Fang iD, Mengjuan Tao iD, Xiaoning Tan iD

Phytotherapy Research · 16.11.2026

DOI: 10.1002/ptr.70527 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Phytotherapy Research, online erschienen am 16.11.2026. Verfasst von Zicheng Liang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Hunan Provincial Hospital of Integrated Traditional Chinese and Western Medicine, the Affiliated Hospital of Hunan Academy of Traditional Chinese Med…. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Key Research and Development Program of Hunan Province of China, Changsha Outstanding Young Scientific and Technological Talent Training Program, Hunan Furong Health Talent Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cisplatin resistance remains a major challenge in non‐small cell lung cancer (NSCLC) therapy. This study investigated whether wogonin, a natural flavonoid, can reverse cisplatin resistance and explored the underlying mechanisms. The effects of wogonin alone and in combination with cisplatin (DDP) were evaluated in DDP‐sensitive (A549) and DDP‐resistant (A549/DDP) NSCLC cells using CCK‐8, colony formation, wound healing, and Transwell assays. Cell death was characterized by measuring ferroptosis markers (ROS, MDA, GSH, JC‐1). Potential targets were identified via RNA sequencing and validated by molecular docking and dynamics simulations. The involvement of the HO‐1/PPARγ/PGC‐1α axis and mitochondrial quality control was assessed using immunofluorescence, western blotting, qPCR, and electron microscopy, with Zinc Protoporphyrin as an HO‐1 inhibitor. In vivo efficacy was confirmed in an NCI‐H1975 xenograft model. Wogonin synergized with DDP to inhibit proliferation, migration, and invasion of A549/DDP cells. The combination synergistically induced ferroptosis, characterized by elevated ROS and MDA, depleted GSH, and downregulated SLC7A11. GPX4 was not examined in the current dataset and will be included in follow‐up studies. Transcriptomic and in silico analyses identified HO‐1, PPARγ, PGC‐1α, and SLC7A11 as potential targets. Functionally, the combination suppressed the HO‐1/PPARγ/PGC‐1α axis and SLC7A11; pharmacological HO‐1 inhibition with ZnPP partially reversed these changes. No genetic causality is claimed. Mechanistically, it disrupted mitochondrial quality control by inhibiting biogenesis (reduced mtDNA transcripts, Nrf1/2) and blocking protective mitophagy (altered LC3B localization, reduced Parkin, accumulated p62). In vivo, the combination potently suppressed tumor growth and downregulated the HO‐1/PPARγ/PGC‐1α axis. These findings suggest that wogonin may reverse cisplatin resistance in NSCLC by inducing ferroptosis and disrupting mitochondrial quality control, potentially through the HO‐1/PPARγ/PGC‐1α axis. This axis should be considered a working hypothesis pending genetic validation.

Schlagwörter

Stichwörter der Autor:innen

HO‐1/PPARγ/PGC‐1α axisNSCLCcisplatin resistanceferroptosismitochondrial biogenesismitochondrial quality controlmitophagywogonin

Autor:innen und Institutionen

  • Hunan Provincial Hospital of Integrated Traditional Chinese and Western Medicine, the Affiliated Hospital of Hunan Academy of Traditional Chinese Medicine, Changsha, China.
  • Zhejiang Chinese Medical University, Hangzhou, China.
  • Hunan University of Chinese Medicine, Changsha, China.

ORCID-Profile: Xiayi Fang, Mengjuan Tao, Xiaoning Tan

Förderung

  • Key Research and Development Program of Hunan Province of China
  • Changsha Outstanding Young Scientific and Technological Talent Training Program
  • Hunan Furong Health Talent Project
  • Backbone Talent Program of the 14th Five-Year Plan of Hunan Province
  • Graduate Student Innovation Project of Hunan University of Chinese Medicine

Zitieren

APA

Liang, Z., Fang, X., Tao, M., & Tan, X. (2026). Wogonin Reverses Cisplatin Resistance of Non‐Small Cell Lung Cancer by Inducing Ferroptosis and Disrupting Mitochondrial Quality Control: A Potential Role of the HO ‐1/ PPARγ / PGC ‐1α Axis. Phytotherapy Research. https://doi.org/10.1002/ptr.70527

Vancouver

Liang Z, Fang X, Tao M, Tan X. Wogonin Reverses Cisplatin Resistance of Non‐Small Cell Lung Cancer by Inducing Ferroptosis and Disrupting Mitochondrial Quality Control: A Potential Role of the HO ‐1/ PPARγ / PGC ‐1α Axis. Phytotherapy Research. 2026. doi:10.1002/ptr.70527

BibTeX
@article{Liang2026,
  author = {Liang, Zicheng and Fang, Xiayi and Tao, Mengjuan and Tan, Xiaoning},
  title = {Wogonin Reverses Cisplatin Resistance of Non‐Small Cell Lung Cancer by Inducing Ferroptosis and Disrupting Mitochondrial Quality Control: A Potential Role of the HO ‐1/ PPARγ / PGC ‐1α Axis},
  journal = {Phytotherapy Research},
  year = {2026},
  doi = {10.1002/ptr.70527}
}
Kostenlos starten →